Triple-negative breast cancer (TNBC), which lacks the expression of both HR and HER2 [11,41], has chemotherapy as the main treatment approach with new approvals of targeted therapy and immune checkpoint inhibitors added [39]. This evidence concerns the gene HR and triple-negative breast carcinoma.